Leo Pharma has stepped up to commercialize toripalimab in Europe, inking a deal with Shanghai Junshi Biosciences to secure ...

Junshi Biosciences enters distribution and marketing partnership with LEO Pharma for toripalimab in Europe: Shanghai, China Wednesday, January 22, 2025, 14:00 Hrs [IST] Shanghai J ...

Shanghai Junshi Biosciences and its subsidiary TopAlliance Biosciences are set to enter a collaboration with LEO Pharma to ...

Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and ...

Gilead will pay LEO Pharma $250 million upfront under the arrangement; further milestone payments may boost the total to $1.7 ...

Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more ...

Gilead Sciences and LEO Pharma have entered a strategic collaboration to expedite the development and commercialisation of ...

Gilead Sciences said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat ...

Biotech giant Gilead Sciences, Inc. GILD has put up a strong performance amid a volatile market. Shares of this biotech giant ...

Gilead Sciences Inc. is moving further into inflammatory diseases in a potential $1.7 billion deal with Leo Pharma A/S around a preclinical oral signal transduction and activator of transcription 6 ...

Gilead Sciences, Inc. (GILD) and LEO Pharma entered strategic partnership to develop and commercialize LEO Pharma's small molecule ...